Search
Meningococcal polysaccharide vaccine group Y
go.drugbank.com/drugs/DB13888ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.
Bendamustine
go.drugbank.com/drugs/DB06769ApprovedInvestigationalBendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). … Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules.
XL019
go.drugbank.com/drugs/DB05243InvestigationalAn IND for XL019 was filed by Exelixis in May 2007.
Dihydro-alpha-ergocryptine
go.drugbank.com/drugs/DB11274ApprovedTo know more about this mixture, please visit [DB01049] … This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine.[T195] Both compounds are hydrogenated ergot derivatives.
Alvocidib
go.drugbank.com/drugs/DB03496InvestigationalIt works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells. … Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer.
Orgotein
go.drugbank.com/drugs/DB11444ExperimentalVet approvedHydrogen peroxide can be degraded by catalase. The antioxidant mechanism of SOD is common to most organisms exposed to oxygen. A notable exception is Lactobacillus plantarum. … Superoxide is a natural byproduct of oxygen metabolism which, if left unchecked, leads to cell damage.
Categories: Analgesics, Non-Narcotic, Antiinflammatory and Antirheumatic Products, Non-SteroidsSYNB1020
go.drugbank.com/drugs/DB17667Investigationaldiscontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. … It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer
Meningococcal polysaccharide vaccine group W-135
go.drugbank.com/drugs/DB13887ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.
AM103
go.drugbank.com/drugs/DB05225ExperimentalAM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation … It is being developed by Amira.
Ambrisentan
go.drugbank.com/drugs/DB06403ApprovedInvestigationalIn addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. … It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening.